Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

‘Wilpon’s Folly’ Explains Einhorn’s Failed $200M Deal with Mets

Greenlight Capital’s David Einhorn’s $200 million deal with the New York Mets was put to bed, not by a change of the hedge fund manager’s mind, but by New York Mets owner Fred Wilpon, or at least that is the assertion in a new book by Howard Megdal, ‘Wilpon’s Folly,’ reports FINAlternatives.

David Einhorn Greenlight Capital

David Einhorn and the New York Mets agreed in May that Einhorn would provide the latter with a $200 million loan, in exchange for a piece of the team. Under the agreement, the Mets would have five years to repay the loan and, if they failed, would be required to sell a majority stake to Einhorn under the terms of the agreement. Wilpon seems to have regretted the deal and sought a way out. So, he asked Selig to kill the provision that would give Einhorn a path to majority ownership of the team. Einhorn caught word of Wilpon’s intentions and walked away from the deal.

“Wilpon asked Selig to strike the provision requiring him to enable and assist David Einhorn in his pursuit of majority ownership, if Wilpon couldn’t repay him,” wrote Howard Megdal in ‘Wilpon’s Folly.’ “The idea would be that Selig would play the bad cop. When Major League Baseball put the kibosh on Einhorn, Wilpon would have plausible deniability, and could throw up his hands and say, ‘What can I do? This is how MLB works.'”

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!